Quoin Pharmaceuticals to Provide Corporate Update and Announce Third Quarter 2025 Financial Results on Thursday, November 6, 2025
Quoin Pharmaceuticals (NASDAQ: QNRX) announced an upcoming corporate update and release of third quarter 2025 financial results on Thursday, November 6, 2025.
The company said it will provide an operational update highlighting key achievements from the quarter, recent accomplishments, and financial highlights for the quarter ended September 30, 2025, with details scheduled to be released before the market opens on November 6, 2025.
Quoin Pharmaceuticals (NASDAQ: QNRX) ha annunciato un imminente aggiornamento aziendale e la pubblicazione dei risultati finanziari del terzo trimestre 2025 il giovedì 6 novembre 2025.
L'azienda ha dichiarato che fornirà un aggiornamento operativo evidenziando i principali risultati del trimestre, i recenti traguardi, e gli accenti finanziari del trimestre conclusosi il 30 settembre 2025, con dettagli previsti per essere pubblicati prima dell'apertura del mercato il 6 novembre 2025.
Quoin Pharmaceuticals (NASDAQ: QNRX) anunció una próxima actualización corporativa y la publicación de los resultados financieros del tercer trimestre de 2025 el jueves 6 de noviembre de 2025.
La compañía dijo que proporcionará una actualización operativa destacando logros clave del trimestre, logros recientes, y aspectos financieros del trimestre terminado al 30 de septiembre de 2025, con los detalles programados para ser publicados antes de la apertura del mercado el 6 de noviembre de 2025.
퀴인 파마슈티컬스(나스닥: QNRX)는 2025년 11월 6일 목요일에 예정된 기업 업데이트와 2025년 3분기 재무 실적 발표를 발표했다.
회사는 분기 운영 업데이트를 제공하며 분기 주요 성과, 최근 성과 및 2025년 9월 30일 종료된 분기의 재무 하이라이트를 강조하고, 자세한 내용은 시장 개장 전에 2025년 11월 6일에 공개될 예정이라고 말했다.
Quoin Pharmaceuticals (NASDAQ : QNRX) a annoncé une prochaine mise à jour de l'entreprise et la publication des résultats financiers du troisième trimestre 2025 le jeudi 6 novembre 2025.
La société a déclaré qu'elle fournirait une mise à jour opérationnelle mettant en évidence les principaux succès du trimestre, les réalisations récentes, et les points saillants financiers du trimestre clos au 30 septembre 2025, avec les détails prévus pour être publiés avant l'ouverture du marché le 6 novembre 2025.
Quoin Pharmaceuticals (NASDAQ: QNRX) kündigte ein bevorstehendes Unternehmensupdate und die Veröffentlichung der Finanzergebnisse des dritten Quartals 2025 am Donnerstag, den 6. November 2025 an.
Das Unternehmen sagte, es werde ein operatives Update bereitstellen, das wichtige Errungenschaften des Quartals, jüngste Erfolge und finanzielle Höhepunkte für das Quartal bis zum 30. September 2025 hervorhebt, wobei Details vor Markteröffnung am 6. November 2025 veröffentlicht werden sollen.
Quoin Pharmaceuticals (NASDAQ: QNRX) أعلنت عن تحديث شركي قريب وإصدار نتائج الربع الثالث من عام 2025 في يوم الخميس، 6 نوفمبر 2025.
قالت الشركة إنها ستقدم تحديثاً تشغيلياً يبرز الإنجازات الرئيسية من الربع، الإنجازات الحديثة و المعالم المالية للربع المنتهي في 30 سبتمبر 2025، مع تفاصيل من المقرر إصدارها قبل فتح السوق يوم 6 نوفمبر 2025.
- None.
- None.
ASHBURN, Va., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to provide an operational update highlighting key achievements from the quarter, recent accomplishments, and financial highlights for the third quarter ended September 30, 2025, before the market opens on Thursday, November 6, 2025.
About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. For more information, go to: www.quoinpharma.com.
For further information, contact:
Quoin Pharmaceuticals Ltd.
Michael Myers, Ph.D., CEO
mmyers@quoinpharma.com
Investor Relations
PCG Advisory
Jeff Ramson
jramson@pcgadvisory.com
(646) 863-6341
FAQ
When will Quoin Pharmaceuticals (QNRX) release its Q3 2025 financial results?
What will Quoin Pharmaceuticals cover in its November 6, 2025 corporate update for QNRX?
How can investors access Quoin Pharmaceuticals' Q3 2025 results for QNRX?
Does the November 6, 2025 announcement include a conference call or webcast for QNRX?
Which quarter do the November 6, 2025 financial highlights for QNRX cover?
Will Quoin Pharmaceuticals' November 6, 2025 release include clinical program updates for QNRX?
